SH-26
SH-26 is a PHD1 PROTAC degrader with DC50s of 1.06 μM, 4.16 μM and 4.91 μM in MDA-MB-231, HepG2 and HEK-293T cells, respectively. SH-26 recruits CRBN to induce PHD1 degradation via the ubiquitin-proteasome system. SH-26 attenuates APAP (HY-66005)-triggered ROS accumulation, mitochondrial dysfunction, and NLRP3 inflammasome activation. SH-26 can be used for the research of acute liver injury.
(Pink: HIF/HIF Prolyl-Hydroxylase ligand (HY-183996); Blue: Cereblon ligand (HY-10984); Black: linker).
For research use only. We do not sell to patients.
- Formula: C38H41N9O8
- Molecular Weight:751.79
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
NLRP3 inflammasome |
PHD1 |
In Vitro
SH-26 (Compound 26) (0.25-10 μM; 2-72 h) induces concentration- and time-dependent PHD1 degradation in MDA-MB-231 cells, with a DC50 of 1.06 μM and a Dmax of 77.5% in 48 h[1].
SH-26 (0.25-50 μM; 48 h) induces concentration-dependent PHD1 degradation in HepG2 cells with a DC50 of 4.16 μM[1].
SH-26 (0-50 μM; 48 h) induces concentration-dependent PHD1 degradation in HEK-293T cells with a DC50 of 4.91 μM[1].
SH-26 (2-25 μM; 48 h) mediates PHD1 degradation in MDA-MB-231, HepG2, and HEK-293T cells in a ubiquitin-proteasome system-dependent manner that requires both PHD1 target engagement and CRBN recruitment[1].
SH-26 (1-25 μM; 4 h pretreatment) degrades PHD1 and PHD2 (but not PHD3) and stabilizes HIF-1α in APAP-challenged AML12 hepatocytes under normoxic conditions[1].
SH-26 (1-25 μM; 4 h pretreatment) exhibits enhanced concentration-dependent PHD1 degradation (DC50 = 0.13 μM) and stabilizes HIF-1α in APAP-challenged AML12 hepatocytes under hypoxic conditions[1].
SH-26 (1-50 μM; 4 h pretreatment) protects AML12 hepatocytes from APAP-induced injury in a concentration-dependent manner without inherent cytotoxicity[1].
SH-26 (1-25 μM; 4 h pretreatment) restores expression of HIF-1α target genes BNIP3 and SLC2A1, does not affect PHD1 mRNA levels, and suppresses IL-1β mRNA levels in APAP-challenged AML12 hepatocytes[1].
SH-26 (1-50 μM; 4 h pretreatment) dose-dependently degrades PHD1 and suppresses IL-1β protein levels in APAP-challenged AML12 hepatocytes[1].
SH-26 (1 μM; 24 h) degrades PHD1 and downregulates pro-inflammatory mediators IL-1β, IL-6, and TNF-α in LPS (HY-D1056)+IFN-γ-stimulated THP-1-derived M1 macrophages[1].
SH-26 (1-25 μM; 4 h pretreatment) dose-dependently reduces mitochondrial reactive oxygen species accumulation in APAP-challenged AML12 hepatocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 breast cancer cells
-
Concentration:0.25μM; 0.5 μM; 1 μM; 2 μM; 2.5 μM; 5 μM; 10 μM
-
Incubation Time:2 h; 4 h; 8 h; 12 h; 24 h; 48 h; 72 h
-
Result:Induced 67% PHD1 degradation at 24 h, 70% at 48 h, and 80% at 72 h at 2 μM.
Induced concentration-dependent PHD1 degradation with a DC50 of 1.06 μM and a maximum degradation (Dmax) of 77.5%.
Caused significant degradation within 4 h, with maximal depletion achieved by 72 h.
Showed no hook effect at concentrations up to 10 μM.
-
Cell Line:HepG2 hepatoma cells
-
Concentration:0.25μM; 0.5 μM; 1 μM; 2.5 μM; 5 μM; 10 μM
-
Incubation Time:48 h
-
Result:Induced concentration-dependent PHD1 degradation with a DC50 of 4.16 μM.
-
Cell Line:HEK-293T embryonic kidney cells
-
Concentration:0.25μM; 0.5 μM; 1 μM; 2.5 μM; 5 μM; 10 μM
-
Incubation Time:48 h
-
Result:Induced concentration-dependent PHD1 degradation with a DC50 of 4.91 μM.
-
Cell Line:MDA-MB-231, HepG2, and HEK-293T cells
-
Concentration:2 μM; 25 μM
-
Incubation Time:48 h
-
Result:Had its PHD1-degrading activity blocked in all three cell lines when cotreated with MG132, MLN4924, Takeda-54, or SH-28.
-
Cell Line:AML12 hepatocytes
-
Concentration:1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM
-
Incubation Time:4 h pretreatment
-
Result:Degraded PHD1 in a concentration-dependent manner.
Degraded PHD2 with a DC50 of 1.83 μM and a Dmax of 71.8%.
Did not degrade PHD3.
Stabilized HIF-1α in a concentration-dependent manner.
-
Cell Line:AML12 hepatocytes
-
Concentration:1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM
-
Incubation Time:4 h pretreatment
-
Result:Exhibited enhanced PHD1 degradation under hypoxia with a DC50 of 0.13 μM.
Stabilized HIF-1α in a concentration-dependent manner.
-
Cell Line:AML12 hepatocytes (APAP-induced injury)
-
Concentration:1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM; 50 μM
-
Incubation Time:4 h pretreatment
-
Result:Attenuated APAP-induced hepatotoxicity in a concentration-dependent manner.
Exhibited no inherent cytotoxicity at tested concentrations.
-
Cell Line:AML12 hepatocytes (APAP-induced injury)
-
Concentration:1 μM; 5 μM; 25 μM
-
Incubation Time:4 h pretreatment
-
Result:Restored BNIP3 mRNA to baseline levels and significantly upregulated SLC2A1 mRNA at 10 μM.
Did not alter PHD1 mRNA levels.
Dose-dependently suppressed IL-1β mRNA levels.
-
Cell Line:AML12 hepatocytes (APAP-induced injury)
-
Concentration:1 μM; 2.5 μM; 5 μM; 10 μM; 25 μM; 50 μM
-
Incubation Time:4 h pretreatment
-
Result:Dose-dependently degraded PHD1.
Dose-dependently suppressed IL-1β protein levels.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | Plasma Concentration |
|---|---|---|---|---|---|
| Mice[1] | 30 mg/kg | i.p. | 7 μM | 0.5 h | ~10 nM |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 8 weeks old, APAP-induced acute liver injury)[1]
-
Dosage:10 mg/kg; 30 mg/kg
-
Administration:i.p.; single dose
-
Result:Significantly reduced serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CRE), and blood urea nitrogen (BUN) at 30 mg/kg.
Markedly attenuated APAP-induced hepatic damage, confirmed by histopathological analysis and necrotic area quantification at 10 mg/kg and 30 mg/kg.
Effectively reversed APAP-induced upregulation of PHD1 protein expression and induced robust PHD1 degradation in liver tissue at 10 mg/kg and 30 mg/kg.
Significantly reduced the upregulation of inflammasome components (NLRP3, GSDMD, cleaved caspase 1, cleaved IL-1β) at 10 mg/kg and 30 mg/kg.
Attenuated pro-apoptotic signals (increased BAX/BCL2 ratio, elevated cleaved caspase 3 levels) at 10 mg/kg and 30 mg/kg.
Significantly reduced liver tissue expression of immune cell markers LY6G, F4/80, CD31, and CD3 at 10 mg/kg and 30 mg/kg.
Chemical Information
-
Molecular Weight 751.79
-
Formula C38H41N9O8
-
SMILES
O=C1N(C(C2=CC=CC(NCCOCCOCCOCCNC(CCNC3=CC4=NC=NN4C(C5=C(C=C(C=C5)C#N)C)=C3)=O)=C21)=O)C6CCC(NC6=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- SH-26
- SH26
- SH 26
- PROTACs
- HIF/HIF Prolyl-Hydroxylase
- Reactive Oxygen Species (ROS)
- NOD-like Receptor (NLR)
- ubiquitin-proteasome system
- NLRP3 inflammasome
- MDA-MB-231 cells
- AML12 hepatocytes
- THP-1-derived M1 macrophages
- HepG2 cells
- PHD1
- cereblon
- HEK-293T cells
- APAP-induced acute liver injury model
- Inhibitor
- inhibitor
- inhibit